Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2015

View Archived Issues

New evidence for the role of HCN channels in the pathogenesis of epilepsy

Coq2 and Plac8 genes in obesity-related type 2 diabetes

MACC1 expression correlates with reduced overall survival in Klatskin tumors

SBIR grant supports Protagonist's development of oral IL-23 receptor antagonists for IBD

Conatus reports results of phase II emricasan portal hypertension trial in liver cirrhosis patients

ADX-71149 synergistic with levetiracetam in preclinical models of epilepsy

EMA CHMP recommends approval of dabigatran reversal agent idarucizumab

Sideromycin-based antibiotics yield positive results against Gram-negative bacteria

Lilly patents BACE1 inhibitors

GlaxoSmithKline describes PERK inhibitors

RaQualia designs TRPM8 antagonists

Chong Kun Dang Holdings discloses HDAC6 inhibitors

A*STAR develops HDAC inhibitors

Hemophilia A therapy Elocta recommended for E.U. approval

CHMP supports approval of Orkambi and expansion of Kalydeco indications

CHMP adopts positive opinion on Gilead's Genvoya for HIV infection

Exelixis' cobimetinib receives positive opinion from CHMP for treatment of melanoma

Intarcia Therapeutics to acquire Phoundry Pharmaceuticals

EMA committee hands down positive opinion for Ravicti

European Cancer Congress: Preliminary efficacy data on roniciclib in ED-SCLC

Regeneron and Sanofi's Praluent approved in E.U. for hypercholesterolemia

FDA approves Tresiba for adults with type 1 or type 2 diabetes

Viekirax approved for treatment of genotype 1 HCV infection in Japan

First results from phase I trial evaluating anti-PTK7 ADC in advanced cancer

Japan first country to approve omarigliptin

Amgen's Kyprolis and Blincyto receive positive opinions from EMA's CHMP

Teva's Copaxone approved in Japan for MS

European committee recommends approval of aflibercept for myopic CNV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...